Bellerophon to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
Bellerophon Therapeutics (Nasdaq: BLPH) announced that CEO Fabian Tenenbaum will provide a corporate overview at the H.C. Wainwright 23rd Annual Global Investment Conference, taking place from September 13-15, 2021. The presentation will be available on-demand starting at 7:00 AM ET on September 13, accessible via the Investors section of the company's website.
Bellerophon focuses on innovative therapies for cardiopulmonary diseases and is developing multiple candidates under the INOpulse® program, a proprietary nitric oxide delivery system.
- None.
- None.
WARREN, N.J., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, today announced that Fabian Tenenbaum, Chief Executive Officer, will present a corporate overview at the H.C. Wainwright 23rd Annual Global Investment Conference, being held September 13-15, 2021.
The presentation will be available on-demand beginning at 7:00 AM Eastern Time on Monday, September 13, 2021, in the Investors section on the Company’s website at www.bellerophon.com.
About Bellerophon
Bellerophon Therapeutics is a clinical-stage biotherapeutics company focused on developing innovative therapies that address significant unmet medical needs in the treatment of cardiopulmonary diseases. The Company is currently developing multiple product candidates under its INOpulse® program, a proprietary pulsatile nitric oxide delivery system. For more information, please visit www.bellerophon.com.
Contacts
LifeSci Advisors:
Brian Ritchie
(212) 915-2578
britchie@lifesciadvisors.com
FAQ
When will Bellerophon Therapeutics present at the H.C. Wainwright Conference?
What time will Bellerophon’s presentation be available?
Where can I watch Bellerophon Therapeutics' presentation?
What does Bellerophon focus on?
What program is Bellerophon currently developing?
